How does PVLA's pb Ratio compare to its peers?

PVLA has negative equity and a Price-To-Book Ratio (-3.6x) compared to the peer average (1.8x).

How does PVLA's pb Ratio compare vs other companies in the US Biotechs Industry?

PVLA has negative equity and a Price-To-Book Ratio (-3.6x) compared to the US Biotechs industry average (1.5x).

What is PVLA's pb Ratio compared to its Fair pb Ratio? This is the expected pb Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate PVLA's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of PVLA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate PVLA's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Palvella Therapeutics (Nasdaq:PVLA) - Stock Price, News & Analysis

PVLA Stock Overview

A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. More details

PVLA fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Revenue is forecast to grow 78.27% per year

Analysts in good agreement that stock price will rise by 34.9%

Risk Analysis

Has less than 1 year of cash runway

Negative shareholders equity

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

Palvella Therapeutics, Inc. Competitors

Acelyrin

NasdaqGS:SLRN

US$262.3m

enGene Holdings

NasdaqCM:ENGN

US$267.1m

iTeos Therapeutics

NasdaqGM:ITOS

US$265.5m

Gossamer Bio

NasdaqGS:GOSS

US$260.6m

Price History & Performance

Summary of share price highs, lows and changes for Palvella Therapeutics
Historical stock prices
Current Share Price	US$27.99
52 Week High	US$28.00
52 Week Low	US$11.17
Beta	0
1 Month Change	80.00%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	118.16%

Recent updates

Shareholder Returns

	PVLA	US Biotechs	US Market
7D	35.2%	1.2%	-4.6%
1Y	n/a	-6.7%	8.8%

Return vs Industry: Insufficient data to determine how PVLA performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how PVLA performed against the US Market.

Price Volatility

Is PVLA's price volatile compared to industry and market?
PVLA volatility
PVLA Average Weekly Movement	10.9%
Biotechs Industry Average Movement	10.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	17.3%
10% least volatile stocks in US Market	3.3%

Stable Share Price: PVLA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine PVLA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	7	Wes Kaupinen	palvellatx.com

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases.

Palvella Therapeutics, Inc. Fundamentals Summary

How do Palvella Therapeutics's earnings and revenue compare to its market cap?
PVLA fundamental statistics
Market cap	US$282.33m
Earnings (TTM)	-US$7.75m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-40.5x

P/E Ratio

Is PVLA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PVLA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$7.75m
Earnings	-US$7.75m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.69
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-143.3%

How did PVLA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/11 02:38
End of Day Share Price	2025/03/11 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Palvella Therapeutics, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Whitney Ijem	Canaccord Genuity
Joshua Schimmer	Cantor Fitzgerald & Co.
Andrew Fein	H.C. Wainwright & Co.

Palvella Therapeutics NasdaqCM:PVLA Stock Report